Results 71 to 80 of about 126,024 (329)

Identification of LDH-A as a therapeutic target for cancer cell killing via (i) p53/NAD(H)-dependent and (ii) p53 independent pathways [PDF]

, 2014
Most cancer cells use aerobic glycolysis to fuel their growth. The enzyme lactate dehydrogenase-A (LDH-A) is key to cancer’s glycolytic phenotype, catalysing the regeneration of nicotinamide adenine dinucleotide (NAD þ ) from reduced nicotinamide adenine
Allison, Simon J., Granchi, C., Knight, J.R.P., Milner, J., Minutolo, F., Phillips, R.M., Rani, R.   +6 more
core   +1 more source

MiRNAs as novel adipokines : obesity-related circulating MiRNAs influence chemosensitivity in cancer patients [PDF]

, 2020
Adipose tissue is an endocrine organ, capable of regulating distant physiological processes in other tissues via the release of adipokines into the bloodstream.
Dewhurst, T, Hammond, CJ, Topham, CH, Withers, SB   +3 more
core   +2 more sources

Histone deacetylases as new therapy targets for platinum-resistant epithelial ovarian cancer [PDF]

, 2016
Introduction: In developed countries, ovarian cancer is the fourth most common cancer in women. Due to the nonspecific symptomatology associated with the disease many patients with ovarian cancer are diagnosed late, which leads to significantly poorer ...
A Hayashi, A Mai, A Saito, A Vannini, A Villar-Garea, AA Lane, AJ Dembo, AJ Wilson, Albandri Alfraidi, AM Abukhdeir, Aun Muhammad, AW Kurian, B Sorbe, BA Goff, BD Strahl, BH Huang, BY Karlan, C Aghajanian, C Bosetti, C Campas-Moya, C Gomez-Raposo, CJ Dunton, CM Grozinger, CS Marcus, CT Lin, D Khabele, D Matei, D Mottet, D Strumberg, D Waltregny, DC Drummond, DD Bowtell, DE Marsden, DK Armstrong, DM Dinulescu, Dmitri Pchejetski, DO Bauerschlag, E Hu, E Smolle, E Verdin, G Piperno, G Tortolero-Luna, H Naora, HA Risch, Heba Alshaker, HL Cheng, I Cetin, IK Kolasa, J Boyd, J Morrison, J Permuth-Wey, J Plisiecka-Halasa, J Prat, J Sonnemann, J Zhang, JA Rauh-Hain, JE Bolden, JE Palmer, JF Stratton, JH Choi, JJ Hwang, JL Benedet, JL MacDonald, JL Walker, JM Piek, JP Secrist, JR Graff, JR Ribeiro, K Kudoh, K Ozaki, K Sawada, K Struhl, KA Lowe, KB Glaser, Keith Sacco, KF McGonigle, KR Cho, L Dai, Leonardo Monzon, M Booth, M Fung-Kee-Fung, M Kartalou, M Markman, M Ohmichi, M Schuijer, MF Fathalla, MJ Piccart, MJ Scanlan, MK Tuxen, ML Friedlander, MM Leitao, MS Finnin, MS Kim, N Einhorn, N Einhorn, N Takai, N Takai, N Takai, NC Hait, NG Gavalas, NS Bese, P Marks, P Zhu, PH Wang, R Furumai, RA Burger, RA Burger, RC Bast Jr, RF Ozols, RL Coleman, RP Warrell Jr, RP Wernyj, S Gregoire, S Rinaldi, S Senese, S Spiegel, SA Cannistra, SA Gayther, SA Gayther, SC Modesitt, SR Wedge, T Meyer, TJ Herzog, TJ Perren, TL Klug, V Auner, V Conteduca, W Fischle, W Weichert, X Qian, YV Shebzukhov   +130 more
core   +1 more source

Effective therapeutic targeting of CTNNB1‐mutant hepatoblastoma with WNTinib

Molecular Oncology, EarlyView.
WNTinib, a Wnt/CTNNB1 inhibitor, was tested in hepatoblastoma (HB) experimental models. It delayed tumor growth and improved survival in CTNNB1‐mutant in vivo models. In organoids, WNTinib outperformed cisplatin and showed enhanced efficacy in combination therapy, supporting its potential as a targeted treatment for CTNNB1‐mutated HB.
Ugne Balaseviciute, Júlia Huguet‐Pradell, Jordi Abril‐Fornaguera, Albert Gris‐Oliver, Alex Rialdi, Elisa Fernández‐Martínez, Carla Montironi, Vanessa Del Pozo, Peter Houghton, Laura Zanatto, Agavni Mesropian, Ieva Keraite, Swan Thung, Carolina Armengol, Pau Sancho‐Bru, Ernesto Guccione, Roser Pinyol, Josep M. Llovet   +17 more
wiley   +1 more source

RNA helicase DDX5 modulates sorafenib sensitivity in hepatocellular carcinoma via the Wnt/β-catenin–ferroptosis axis

Cell Death and Disease, 2023
Reduced expression of the RNA helicase DDX5 associated with increased hepatocellular carcinoma (HCC) tumor grade and poor patient survival following treatment with sorafenib.
Zhili Li, Claude Caron de Fromentel, Woojun Kim, Wen-Hung Wang, Jiazeng Sun, Bingyu Yan, Sagar Utturkar, Nadia Atallah Lanman, Bennett D. Elzey, Yoon Yeo, Hao Zhang, Majid Kazemian, Massimo Levrero, Ourania Andrisani   +13 more
doaj   +1 more source

New insights into the pathogenesis and treatment of non-viral hepatocellular carcinoma: a balancing act between immunosuppression and immunosurveillance. [PDF]

, 2018
Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related deaths worldwide. HCC initiates as a consequence of chronic liver damage and inflammation caused by hepatitis B and C virus infections, excessive alcohol consumption, or non ...
Karin, Michael
core   +1 more source

Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.

JAMA Oncology, 2019
Importance Sorafenib is the first-line treatment for hepatocellular carcinoma with portal vein invasion; however, it has shown unsatisfactory survival benefit. Sorafenib plus hepatic arterial infusion chemotherapy (HAIC) of oxaliplatin, fluorouracil, and
M. He, Qi-Jiong Li, Ruhai Zou, Jingxian Shen, Wanqiang Fang, Guosheng Tan, Yuanmin Zhou, Xiaoping Wu, Li Xu, Wei Wei, Yong Le, Zhongguo Zhou, Ming Zhao, Ying Guo, R. Guo, Minshan Chen, M. Shi   +16 more
semanticscholar   +1 more source

Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma

JAMA Network Open, 2021
Key Points Question Compared with sorafenib, is atezolizumab plus bevacizumab cost-effective as first-line treatment of unresectable hepatocellular carcinoma?
D. Su, Bin Wu, Lizheng Shi
semanticscholar   +1 more source

Targeting p38α in cancer: challenges, opportunities, and emerging strategies

Molecular Oncology, EarlyView.
p38α normally regulates cellular stress responses and homeostasis and suppresses malignant transformation. In cancer, however, p38α is co‐opted to drive context‐dependent proliferation and dissemination. p38α also supports key functions in cells of the tumor microenvironment, including fibroblasts, myeloid cells, and T lymphocytes.
Angel R. Nebreda
wiley   +1 more source

Mitochondrial GCN5L1 acts as a novel regulator for iron homeostasis to promote sorafenib sensitivity in hepatocellular carcinoma

Journal of Translational Medicine
Background Sorafenib resistance is becoming increasingly common and disadvantageous for hepatocellular carcinoma (HCC) treatment. Ferroptosis is an iron dependent programmed cell death underlying the mechanism of sorafenib.
Xiuya Hu, Peiyu Zhang, Sai Li, Jiaqi Zhang, Danni Wang, Zihan Wang, Lu Zhu, Lingdi Wang   +7 more
doaj   +1 more source